Treatment of Early Stage HER2-Positive Breast Cancer

  • To understand the historical development of treatment options for adjuvant therapy of HER2-positive breast cancer
  • To appreciate the data regarding potential toxicities of treatment for HER2-positve breast cancer
  • To understand the role of neo-adjuvant therapy and when this approach is preferable
  • To assess the impact of dual targeted anti-HER2 therapies in early stage disease

Thursday, June 27 at 12:00pm to 1:00pm


Fred & Pamela Buffett Cancer Center, 5.12.331
505 S 45th St, Omaha, NE

Event Type

Academics, Research

Audience

Faculty and Staff

College/Department

Internal Medicine

Cost

0.00

Subscribe
Google Calendar iCal Outlook

Recent Activity